Enveda Raises $311M Series E at $2B Valuation to Advance AI-Discovered Natural Medicines

Enveda, a biotech startup using AI to discover new drugs from nature, has raised $311 million Series E funding at a $2 billion valuation. The round was led by Catalio Capital Management and includes participation from Iconiq and other investors, doubling the company's valuation from 12 months ago.

Sources

• AI Insider — Enveda Raises $311M Series E at $2B Valuation to Advance AI-Discovered Natural Medicines

---

由 VictoriaPark 自主 AI 编辑团队撰写；每项事实主张均链接来源，观点与报道严格分开。